Clinical Trial

Combined Therapy Using Gemcitabine and Cisplatin Chemotherapy, Lenvatinib and Adebrelimab for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 3, 2024 (before its estimated February 25, 2025 completion). Its status may not reflect the trial's current state.
Summary
In this phase 2 study, the investigators aim to evaluate the efficacy and safety of combined therapy using gemcitabine and cisplatin chemotherapy, Lenvatinib and Adebrelimab for patients with advanced and unresectable intrahepatic cholangiocarcinoma
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-03-01.
Trial Details
NCT Number NCT06298968
Lead Sponsor Nanfang Hospital, Southern Medical University
Conditions Intrahepatic Cholangiocarcinoma
Enrollment 38 participants
Start Date 2024-04-26
Primary Completion 2025-02-25 (estimated)
Study Completion 2027-02-25 (estimated)
Updated on ClinicalTrials.gov 2024-07-03